A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

被引：0
|
作者：
Hong, Hyeyeon [1 ]
Choi, Jonggi [1 ]
机构：
[1] Univ Ulsan, Asan Med Ctr, Ctr Liver, Coll Med,Dept Gastroenterol, 88 Olymp ro 43 gil, Seoul 05505, South Korea
来源：
KOREAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 83卷 / 06期
关键词：
D O I：
10.4166/kjg.2024.048
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：253 / 255
页数：3
相关论文
共 50 条
  • [31] Using machine learning models to predict baseline fibrosis stage in patients from phase 3 resmetirom trials (MAESTRO-NAFLD and MAESTRO-NASH)
    Schattenberg, Joern M.
    Anstee, Quentin M.
    Harrison, Stephen A.
    Noureddin, Mazen
    Taub, Rebecca
    Labriola, Dominic
    Priel, Jan
    Padmanabhan, Krishna
    JOURNAL OF HEPATOLOGY, 2024, 80 : S611 - S611
  • [32] Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
    Loomba, Rohit
    Sanyal, Arun J.
    Kowdley, Kris V.
    Bhatt, Deepak L.
    Alkhouri, Naim
    Frias, Juan P.
    Bedossa, Pierre
    Harrison, Stephen A.
    Lazas, Donald
    Barish, Robert
    Gottwald, Mildred D.
    Feng, Shibao
    Agollah, Germaine D.
    Hartsfield, Cynthia L.
    Mansbach, Hank
    Margalit, Maya
    Abdelmalek, Manal F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (11): : 998 - 1008
  • [33] ARTIFICIAL INTELLIGENCE-BASED MEASUREMENT OF NASH HISTOLOGY (AIM-NASH) RECAPITULATES PRIMARY RESULTS FROM PHASE 3 STUDY OF RESMETIROM FOR TREATMENT OF NASH/MASH
    Iyer, Janani S.
    Bedossa, Pierre
    Guy, Cynthia D.
    Baker, Brian Hartman
    Fahy, Darren
    Parker-Shen, Tayla
    Makawana, Darshit
    Glickman, Jonathan
    Labriola, Dominic
    Beck, Andrew H.
    Taub, Rebecca A.
    Harrison, Stephen A.
    HEPATOLOGY, 2024, 79 (02) : E56 - E57
  • [34] Commentary on "Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod"
    Nathens, Avery B.
    ANNALS OF SURGERY, 2020, 272 (03) : 479 - 480
  • [35] Randomized Trial of Pegozafermin in NASH
    Patoulias, Dimitrios
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (23): : 2209 - 2210
  • [36] THE BENEFICIAL EFFECT OF ANGIOTENSIN-BLOCKING AGENT ON LIVER FIBROSIS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL
    Kim, Moon Young
    Baik, Soon Koo
    Jang, Yoon Ok
    Yea, Chang Jin
    Won, Chan Sik
    Byun, Jang Won
    Choi, Hoon
    Cho, Mee-Yon
    HEPATOLOGY, 2009, 50 (04) : 812A - 813A
  • [37] THE BENEFICIAL EFFECT OF ANGIOTENSIN-BLOCKING AGENT ON LIVER FIBROSIS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL
    Kim, M. Y.
    Cho, M. Y.
    Baik, S. K.
    Won, C. S.
    Byun, J. W.
    Park, H. J.
    Choi, H. J.
    Chun, H. K.
    Park, S. Y.
    Kwon, Y. H.
    Cheon, G. J.
    Kim, Y. D.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S44 - S45
  • [38] A randomized controlled trial of a 3-year home exercise program in cystic fibrosis
    Schneiderman-Walker, J
    Pollock, SL
    Corey, M
    Wilkes, DD
    Canny, GJ
    Pedder, L
    Reisman, JJ
    JOURNAL OF PEDIATRICS, 2000, 136 (03): : 304 - 310
  • [39] BASELINE CHARACTERISTICS IN WELL-COMPENSATED NASH CIRRHOSIS PATIENTS DIAGNOSED WITH OR WITHOUT A LIVER BIOPSY IN MAESTRO-NASH-OUTCOMES, A CLINICAL OUTCOME PHASE 3 STUDY ASSESSING THE EFFECT OF RESMETIROM IN WELL COMPENSATED NASH CIRRHOSIS
    Bansal, Meena
    Schattenberg, Joern
    Kowdley, Kris
    Noureddin, Mazen
    Loomba, Rohit
    Taub, Rebecca
    Labriola, Dominic
    Schneider, David
    HEPATOLOGY, 2024, 80 : S645 - S647
  • [40] No benefit with cenicriviroc for liver fibrosis in NASH
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (06): : 508 - 508
12345